Cancer is a leading cause of death in both humans and pets; studies suggest that between one-third and one-half of all dogs ...

The U.S. Food and Drug Administration (FDA) has granted full approval of Laverdia, a drug to treat dogs with lymphoma, a type ...

The FDA has granted full approval to verdinexor tablets (Laverdia; Anivive Lifesciences) for the treatment of dogs with lymphoma. The approval gives veterinarians a promising new oral avenue for ...

The IDEXX Cancer Dx Panel has already transformed cancer screening for veterinarians. Today, more than 5,500 practices across ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

VolitionRx Limited ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in ...

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Christina Urrutia Urena, who began her rescue operation in 2024, claims to have successfully placed more than 100 dogs with ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most often in children and young adults. In recent years, CAR-T cell therapy—often ...

Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...